Serialization and aggregation

We are experts in the final assembly and secondary packing of vials, pre-filled syringes and autoinjectors. From low-medium volumes, variable batch sizes and multi-SKUs requiring a manual or semi-automated process, through to fully automated high-volume processes. We work with you to customize ou...

Our award-winning device design capability, along with our cleanroom injection molding, assembly and validation services, make us an ideal partner if your drug product requires an adapted or proprietary delivery device solution.
We have the manufacturing scale, flexibility and expertise for ...

We have over 20 years’ experience managing sterilization of medical devices

The demand for single use sterile medical devices is growing, and there are real benefits to externalizing your sterilization to a specialist service provider. Ensera’s long-standing relationshi...

Maintain the sterility of your medical device or combination product from production to point of care
Guaranteeing the Sterility Assurance of your medical device for transportation, storage and uncompromised patient safety is one of the main challenges facing the industry. With our understanding of ...

Ready-to-use (RTU), pre-processed primary packaging components such as caps, stoppers and syringe plungers destined for distribution in the EU must comply with the updated requirements set out in Annex 1 of the European Commission’s Good Manufacturing Guidelines (GMP).

...

The accurate preparation of drug delivery sets with multiple components for self-administered drug therapies is complex, time and labor intensive. As a trusted partner to some of the leading pharmaceutical innovators, our turnkey service takes you from process set-up through inspection, labeling and s...

Presenting a partnership between Ensera Design & AstraZeneca to design and develop a combination drug delivery packaging ecosystem at pace and without compromise. Lucy Baldwin will take you through how Inclusive Design methodologies and Finite Element Analysis were used in combination to maximise user value and minimise risk to take AstraZeneca from contextual research discovery to design freeze in 8 months.

Pharma's Global Economic Outlook: Balancing Regional Challenges with International Opportunities

The Pharma industry is being hit simultaneously by multiple, highly complex, rapidly changing issues - ranging from next-generation innovation powered by AI through to unstable tariff regimes, pricing negotiations, regional manufacturing risks and supply chain issues, regulatory harmonisation and so on. Yet at the same time we are seeing huge opportunities created by blockbuster therapies for conditions such as obesity. How do we navigate these complexities, to accelerate drug discovery, development, and approval, while managing costs and risks? Key to this will be winning the public debate about the importance of a well-funded, vibrant, Pharma industry, on which the future health of humanity will depend.